Effect of colony‑stimulating factor in the mechanism of bone metastasis development (Review)

Oncol Rep. 2024 Dec;52(6):165. doi: 10.3892/or.2024.8824. Epub 2024 Oct 18.

Abstract

Bone metastasis (BM) is a common complication of cancer and contributes to a higher mortality rate in patients with cancer. The treatment of BM remains a significant challenge for oncologists worldwide. The colony‑stimulating factor (CSF) has an important effect on the metastasis of multiple cancers. In vitro studies have shown that CSF acts as a cytokine, promoting the colony formation of hematopoietic cells by activating granulocytes and macrophages. Other studies have shown that CSF not only promotes cancer aggressiveness but also correlates with the development and prognosis of various types of cancer. In recent years, the effect of CSF on BM has been primarily investigated using cellular and animal models, with limited clinical studies available. The present review discussed the composition and function of CSF, as well as its role in the progression of BM across various types of cancer. The mechanisms by which osteoclast‑ and osteoblast‑mediated BM occur are comprehensively described. In addition, the mechanisms of action of emerging therapeutic agents are explored for their potential clinical applications. However, further clinical studies are required to validate these findings.

Keywords: granulocyte colony-stimulating factor; granulocyte‑macrophage colony-stimulating factor bone metastasis; macrophage colony‑stimulating factor; osteoblast; osteoclast.

Publication types

  • Review

MeSH terms

  • Animals
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / secondary
  • Colony-Stimulating Factors / therapeutic use
  • Humans
  • Osteoblasts / drug effects
  • Osteoblasts / metabolism
  • Osteoblasts / pathology
  • Osteoclasts* / drug effects
  • Osteoclasts* / metabolism
  • Osteoclasts* / pathology
  • Prognosis

Substances

  • Colony-Stimulating Factors

Grants and funding

The present study was supported by Hubei Province Key Laboratory of Molecular Imaging (grant no. 2023fzyx025 to HJB), Jingzhou 2023 Medical Health Science and Technology Plan Project (grant no. 2023HC07 to HJB), Hubei Provincial Natural Science Foundation (grant no. 2023AFB969 to HJB). Jingzhou Science and Technology Bureau Project (grant no. 2022HC78 to PXC) and Wujieping Medical Foundation digestive tract cancer research fund (grant no. 320.6750.2024–10-3 to PXC).